Dr. Reid is a Director with Monument Analytics. She has a passion for leveraging data and analytics to enhance the client value story for innovative technologies. Dr. Reid has responsibilities in both business and consulting at Monument Analytics.
Dr. Reid’s previous experience ranges from evidence development, cost-effectiveness, and large dataset analyses to inform reimbursement and coverage policy strategy. Her experience in thinking strategically with analytics spans from her time implementing digital registries at Hospital for Special Surgery, to working at the Center for Medicaid and Medication Innovation (CMMI), to digital health strategy, analysis, and implementation at Kaiser Permanente, to working with cell and gene therapy companies on value dossiers as a Director at the reimbursement consulting firm, ADVI Health. Dr. Reid also has expertise in digital health reimbursement, strategy, and implementation across all stages of the life cycle. She has frequently worked on value propositions and strategy for alternative payment models, Medicare Advantage, nutrition, and disease management.
Dr. Reid received her B.A. in the History of Science/History of Medicine from Yale University, her PhD in Health and Public Policy and MPH from the Bloomberg School of Public Health, and MBA from Carey Business School.
Francine Chingcuanco’s background is in epidemiology and pharmacology. Prior to joining Monument, she consulted for the Health Outcomes Research Department of Millennium Health wherein she designed and managed clinical research studies aimed at developing real-world evidence to support products in the field of personalized medicine. She received her Masters in Health Science from Johns Hopkins Bloomberg School of Public Health as well as an Honours Bachelor of Science from the University of Toronto.
Benjamin Cohen specializes in health economics and outcomes research. He received his PhD from the University of Southern California School of Pharmacy where he evaluated the costs and benefits of spending in chronic diseases using administrative claims, microsimulations, and survey data. Prior to starting his doctorate program, he received a Masters in Public Health from Columbia University Mailman School of Public Health. He has previous experience working in the pharmaceutical and biotechnology industry.
Karen Dietz, MHS, Manager, specializes in complex project management, outcomes research, and vaccines. Previously, she worked as a management consultant with enterprise clients across a variety of sectors, including life sciences and pharmaceutical industries. Karen has experience managing multiple outcomes-based research programs and clinical trials at the Johns Hopkins School of Medicine. Karen received her Master of Health Science from Johns Hopkins Bloomberg School of Public Health, with a Certificate in Vaccine Science and Policy, and a Bachelor of Science from Virginia Tech.
Elena Fernandez specializes in pharmacoeconomics and health outcomes. She received her PhD from the Department of Pharmacotherapy and Outcomes Sciences at Virginia Commonwealth University, where she designed and conducted research applying econometric models to evaluate opioid utilization in cancer survivors. Prior to her graduate training, she worked as a cancer research training award (CRTA) fellow at the National Cancer Institute. She also received a Doctor of Pharmacy from Virginia Commonwealth University and a Bachelor of Science in biochemistry from the University of Mary Washington.
Omar Mansour specializes in the application of pharmacoepidemiology methods. Prior to joining Monument, he was a scholar at the Johns Hopkins Bloomberg School of Public Health’s Center for Drug Safety and Effectiveness where he designed and conducted comparative effectiveness studies on various topics using electronic medical records, commercial insurance claims, and large national surveys. He received his Masters in Health Science from Johns Hopkins Bloomberg School of Public Health and a Bachelor of Arts in biology with a minor in statistics from Macalester College.
Katharine Ozenberger specializes in epidemiology and pharmacoepidemiology. She is a PhD candidate in the Department of Pharmacy Systems, Outcomes, and Policy at the University of Illinois at Chicago where she designs and conducts research using longitudinal data from population-based cohorts, prescription dispensing, and commercial insurance claims. She received her Masters in Science in epidemiology from the University of Illinois at Chicago’s School of Public Health and a Bachelor of Science in biology from the University of Colorado Denver.
Eileen Rosello, Senior Analyst, specializes in clinical research and project management. Prior to joining Monument Analytics, she worked as a research program coordinator inthe setting of academia at Johns Hopkins School of Medicine and private enterprise. Eileen has experience managing end-to-end operations for an expansive array of clinical protocols in oncology, transplant epidemiology, and behavioral pharmacology. She received her Bachelor of Arts in Natural Sciences from Johns Hopkins University and has completed graduate coursework in Molecular and Cellular Biology at Johns Hopkins Bloomberg School of Public Health.
Rachel Nadboy supports Monument’s work as an analyst through epidemiological research, analysis, and providing support to team members across multiple work streams including litigation. She received a Bachelor of Arts in History and Science from Harvard College, where she researched the history of occupational health for her senior thesis and was interested in the interaction between the social sciences and the life sciences.
Danyang Wang specializes in economic modeling and cost-effectiveness analysis. Before joining Monument Analytics she developed probabilistic Markov models to assess the cost-effectiveness of community health interventions while in training at Johns Hopkins Bloomberg School of Public Health. She received her Master of Health Science from Johns Hopkins Bloomberg School of Public Health and a Bachelor of Science in Biology with a minor in Economics from Emory University.
Ellen Hu specializes in economic evaluation and has background in healthcare actuarial modeling. Prior to joining Monument, she worked in actuarial consulting where she performed valuations and projections for public and private employer sponsored retiree health plans as well as performed health plan rate settings and design modeling. She received her Master of Health Science from Johns Hopkins Bloomberg School of Public Health and a Bachelor of Arts in Economics with a minor in Mathematics from DePauw University.
Divya Mohan’s background is in health economics and biomedical engineering. She specializes in patient preferences and cost-effectiveness analysis. Previously she worked at the Economist Intelligence Unit on projects including concept testing, communications strategy, market sizing, as well as customer perception and insight studies for imaging systems, in-vitro diagnostics, surgical devices, and procedures. She received her Masters in Health Science from Johns Hopkins Bloomberg School of Public Health and a Bachelor of Engineering from Nanyang Technological University.
Emma Tassie specializes in economic evaluation and patient preferences. She is a PhD candidate in the Health Economics Research Unit (HERU), University of Aberdeen, where she is investigating the use of existing data to incorporate broader measures of benefit in economic evaluation. Prior to her PhD, Emma worked as a researcher at HERU where she conducted economic evaluations alongside randomized controlled trials and developed health economic models to accompany systematic reviews. She received her Masters in Science in Health Economics and a Bachelor of Arts (Economics and Sociology) from University College Cork.
Jeromie Ballreich is an Assistant Scientist and Director of the Master of Health Sciences in Health Economics program in the Department of Health Policy and Management at Johns Hopkins Bloomberg School of Public Health. He received his Ph.D. in Health Economics from Johns Hopkins Bloomberg School of Public Health with a thesis in “Price Discrimination in the US Cancer Drug Market.” Previously, Dr. Ballreich received his Master in Health Economics also from JHSPH and a Bachelors in Mathematics and Economics from Lafayette College.
Dr. Hazard has over twenty years of experience working as a health care consultant. She was a founding leader of Value Medics Research, Inc. Her specialty is value development and value communications. She was an early pioneer in creating value development plans for medical technologies and facilitated the understanding of how demonstrations of economic value could be used effectively by product development and marketing teams. Dr. Hazard has worked with major pharmaceutical companies in the U.S. and Europe and on dozens of medical technologies
Daniel Touchette is Professor and Director of Graduate Studies for the Masters in Comparative Effectiveness Research program at the University of Illinois at Chicago’s College of Pharmacy. His primary research interests are evaluating the cost-effectiveness of pharmaceutical agents assessing the effectiveness and cost-effectiveness of clinical pharmacist and other health practitioner services, and developing and assessing methods for improving adherence to medication regimens. Dr. Touchette has obtained grant funding from AHRQ, NIH, and numerous foundations and other sources. Most recently, he has developed decision models for the Institute for Clinical and Economic Review (ICER) and leads UIC’s involvement in ICERs Health Economic Network. He has authored over 70 peer-reviewed manuscripts and reports.
Dr. Brett McQueen is currently a tenure-track Assistant Professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and a member in the Center for Pharmaceutical Outcomes Research (CePOR). His research interests include comparative effectiveness research, cost-effectiveness applications and methods development, value-based outcomes contracting, and patient preferences research. He’s active in health economics-related societies such as the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) through contributions to ISPOR short courses, workshops, issue panels, and research presentations. Dr. McQueen has led or collaborated on modeling submissions for various health technology assessment groups since 2016. He has authored over 50 publications in journals such as PharmacoEconomics, Diabetes Care, and Medical Care.
Adrian R. Levy PhD is Professor in the Department of Epidemiology and Community Health at Dalhousie University. He is author of over 150 peer reviewed publications and is the co-editor of two volumes in the Springer Handbook of Health Services Research entitled “Comparative Effectiveness Research” and “Health Services Evaluation”. His academic interests lie in health services research, health technology assessment, pharmacoepidemiology, pharmacoeconomics, quality of life, and access to care.
Mark Sculpher is Professor of Health Economics at the Centre for Health Economics, University of York, UK where he leads the Centre’s Programme on Economic Evaluation and Health Technology Assessment. He is also Co-Director of the Policy Research Unit in Economic Evaluation of Health and Care Interventions, a programme of research for the UK Department of Health and Social Care funded by the National Institute for Health Research (NIHR).
Mark has worked in the field of economic evaluation and health technology assessment for over 30 years. He has researched in a range of clinical areas including heart disease, cancer, diagnostics, and public health. He has also contributed to research methods in the field, in particular relating to decision analytic modelling and techniques to handle uncertainty, heterogeneity and generalisability. He is also experienced in economic analysis in low income settings and is principle investigator of the Thanzi la Onse (Health for All) programme in Malawi funded by UK Research and Innovation. He has over 270 peer-reviewed publications and is a co-author of two major text books in the area: Methods for the Economic Evaluation of Health Care Programmes (OUP, 2015 with Drummond, Claxton, Torrance and Stoddart) and Decision Modelling for Health Economic Evaluation (OUP, 2006 with Briggs and Claxton).
Mark is an emeritus member of the UK NIHR College of Senior Investigators. Hehas also been a member of the National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Committee and the NICE Public Health Interventions Advisory Committee. He currently sits on NICE’s Diagnostics Advisory Committee. He chaired NICE’s 2004 Task Group on methods guidance for economic evaluation and advised the Methods Working Party for the 2008 update of this guidance. Mark has advised the UK House of Commons Health and Social Care Select Committee, as well as health systems internationally on health technology assessment methods including those in France, Ireland, Japan, Singapore, Germany, Portugal, Taiwan and New Zealand. He has been a member of the Commissioning Board for the UK NHS Health Technology Assessment Programme, the UK NIHR /Medical Research Council’s Methodology Research Panel and the UK Department of Health’s Policy Research Programme’s Commissioning Panel. He served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (2011-12).
Rob is currently the President of R2 Medical Solutions. Rob advises small- to mid-size domestic and international companies in the biotechnology, pharmaceutical, and medical device sectors on strategy and commercial execution in the US.
With more than two decades of experience, Rob has driven multi-million-dollar revenue growth for market leading companies in Oncology, Wound Care, Pressure Injury Prevention, and Infection Control. As President, US at Molnlycke Health Care, Rob differentiated their product solutions with clinical and health economics outcomes data.
Since 2014, Rob has been on the board of Debra of America and currently serves as the Chief Development Officer (CDO) and Chief Operating Officer (COO). Debra of America is dedicated to improving the quality of life of all people living with Epidermolysis Bullosa (EB) by providing free programs and services and funding innovative research.
Rob received an Executive MBA in Leadership from the University of Georgia, Terry College of Business, a BS in Marketing Management from Valparaiso University, and a Certificate in Leadership from the University of Virginia Darden School of Business.